Age-Related Macular Degeneration

In this video, Barbara Blodi, MD, discusses advancements in gene therapy for the treatment of age-related macular degeneration.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Kelley Sheets of Eyedaptic gives an overview of the Eye6 wearable vision aid for patients with age-related macular degeneration.

Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.

Icare Finland Oy, a subsidiary of Revenio Group, has signed an agreement to acquire the AI software company Thirona Retina, according to a press release.

Healio’s recent FDA news in ophthalmology includes the approval of Enzeevu for neovascular age-related macular degeneration and a rare pediatric disease designation for an X-linked retinoschisis candidate.

Healio spoke with Bradley Dougherty, OD, PhD, associate professor at The Ohio State University College of Optometry, about how socioeconomic factors can affect the diagnosis, treatment and outcomes of age-related macular degeneration.

Eye6 with Ivy, a new wearable vision aid with an interactive AI visual assistant for individuals with age-related macular degeneration and other retinal disorders, is now available, according to a press release from Eyedaptic.

Patient education materials related to age-related macular degeneration treatment are often written at inappropriate reading levels and lack accountability, according to a presentation at the American Society of Retina Specialists meeting.

The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of neovascular age-related macular degeneration, according to a press release from Sandoz.